SIGA
What one share of Siga Technologies holds
Pharmaceutical Preparations
We are a commercial-stage pharmaceutical company. The Company sells its lead product, TPOXX® (“oral TPOXX®,” also known as "tecovirimat," "Tecovirimat-SIGA," or "TEPOXX (tecovirimat)" in certain international markets), to the U.S.
Siga Technologies’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.74 |
|---|---|
| Profit | −$0.04 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.28 |
| Dividends | $0.60 |
| Cash and investments | $1.64 |
| Book value | $2.30 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | — | −$0.52 | $0.01 | −$0.24 | — | −$0.34 |
| 2010 | — | −$1.12 | $0.01 | −$0.25 | — | −$0.26 |
| 2012 | — | −$0.27 | $0.01 | −$0.40 | — | $0.55 |
| 2013 | — | −$0.33 | $0.02 | $1.10 | — | $0.32 |
| 2014 | — | −$4.97 | $0.00 | $0.26 | — | −$4.61 |
| 2015 | — | −$0.73 | $0.00 | $0.20 | — | −$3.61 |
| 2016 | $0.26 | −$0.69 | $0.00 | −$2.04 | — | −$3.64 |
| 2017 | $0.16 | −$0.46 | $0.00 | −$0.23 | — | −$4.00 |
| 2018 | $5.77 | $5.10 | $0.00 | $0.83 | — | $1.27 |
| 2020 | $1.57 | $0.71 | $0.00 | $0.90 | — | $1.68 |
| 2021 | $1.75 | $0.91 | $0.00 | $0.15 | — | $2.37 |
| 2022 | $1.51 | $0.46 | $0.00 | $0.57 | $0.45 | $2.34 |
| 2023 | $1.95 | $0.95 | $0.00 | $1.32 | $0.45 | $2.77 |
| 2024 | $1.93 | $0.82 | $0.00 | $0.68 | $0.60 | $3.02 |
| 2025 | $1.32 | $0.32 | $0.00 | $0.60 | $0.60 | $2.78 |